Inovio Acquires Bioject’s Assets for $5.5M

Inovio Pharmaceuticals has entered an agreement to gain all of Bioject Medical Technologies’ assets for $4.5 million in stock and $1 million in cash.

Inovio plans to launch a device combining its needleless, skin-surface electroporation technology with Bioject’s jet injection technology.

“Similar to our past acquisitions of Advisys and Inovio AS, this purchase of Biojects’s superior jet injection technology and well-positioned patents is an investment in Inovio’s future,” said Inovio CEO J. Joseph Kim.  —  Anisa Jibrell